NEW YORK - Better Choice Company (NYSE: BTTR), a provider of pet health and wellness products, announced today its plans to explore potential partnerships to support and fund its research and development platform. The company recently completed the acquisition of Aimia and is now seeking to monetize its ownership in an R&D project focused on developing a treat-based GLP1 supplement aimed at combating obesity in dogs and cats.
The company's move comes as part of its broader strategy to expand its product offerings and address growing health concerns among pet owners. Obesity in pets has been recognized as a significant health issue, with many dogs and cats suffering from weight-related conditions that can impact their quality of life and longevity.
Better Choice's interest in developing a GLP1 supplement is part of its commitment to providing science-based nutritional products for pets. The company's Halo brand already offers a variety of pet foods, treats, and supplements designed to promote the health and well-being of dogs and cats.
The decision to seek partners for this initiative indicates Better Choice's intention to leverage external expertise and resources to bring the new supplement to market. The company has not yet disclosed specific details about potential partners or the financial structure of such partnerships.
This announcement contains forward-looking statements, and the company acknowledges that not all anticipated results may be achieved. The company will not be obligated to update any forward-looking statements as new information or future events unfold.
Investors and the market will be watching closely as Better Choice evaluates proposals and moves forward with its plans. The success of this venture could have implications for the company's growth and position in the competitive pet health and wellness industry.
The information for this article is based on a press release statement from Better Choice Company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.